MX2023003350A - Tratamiento para el vomito y la nausea con una dosis minima de olanzapina. - Google Patents
Tratamiento para el vomito y la nausea con una dosis minima de olanzapina.Info
- Publication number
- MX2023003350A MX2023003350A MX2023003350A MX2023003350A MX2023003350A MX 2023003350 A MX2023003350 A MX 2023003350A MX 2023003350 A MX2023003350 A MX 2023003350A MX 2023003350 A MX2023003350 A MX 2023003350A MX 2023003350 A MX2023003350 A MX 2023003350A
- Authority
- MX
- Mexico
- Prior art keywords
- olanzapine
- vomiting
- nausea
- treatment
- minimum dose
- Prior art date
Links
- 206010047700 Vomiting Diseases 0.000 title abstract 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005017 olanzapine Drugs 0.000 title abstract 2
- 206010028813 Nausea Diseases 0.000 title 1
- 230000008693 nausea Effects 0.000 title 1
- 230000008673 vomiting Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan equipos, composiciones, dispositivos y métodos para la administración de olanzapina. También se proporcionan los usos de los mismos para tratar la náusea y el vómito.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063083759P | 2020-09-25 | 2020-09-25 | |
US202063083774P | 2020-09-25 | 2020-09-25 | |
PCT/US2021/051868 WO2022066987A1 (en) | 2020-09-25 | 2021-09-24 | Treatment of vomiting and nausea with minimum dose of olanzapine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003350A true MX2023003350A (es) | 2023-03-29 |
Family
ID=78179544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003350A MX2023003350A (es) | 2020-09-25 | 2021-09-24 | Tratamiento para el vomito y la nausea con una dosis minima de olanzapina. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240009204A1 (es) |
EP (1) | EP4216959A1 (es) |
JP (1) | JP2023542937A (es) |
KR (1) | KR20230074518A (es) |
CN (1) | CN116209428A (es) |
AU (1) | AU2021349936A1 (es) |
CA (1) | CA3193237A1 (es) |
MX (1) | MX2023003350A (es) |
WO (1) | WO2022066987A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023134641A1 (zh) * | 2022-01-12 | 2023-07-20 | 新领医药技术(深圳)有限公司 | 奥氮平透皮给药系统及其制备方法和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2546200A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
WO2020131915A1 (en) * | 2018-12-17 | 2020-06-25 | Starton Therapeutics, Inc. | Use of olanzapine for treatment of parp-inhibitor-induced nausea |
CN114901287A (zh) * | 2020-01-13 | 2022-08-12 | 斯塔顿治疗公司 | 用最小剂量的奥氮平治疗呕吐和恶心 |
-
2021
- 2021-09-24 AU AU2021349936A patent/AU2021349936A1/en active Pending
- 2021-09-24 CN CN202180066038.7A patent/CN116209428A/zh not_active Withdrawn
- 2021-09-24 CA CA3193237A patent/CA3193237A1/en active Pending
- 2021-09-24 EP EP21791557.8A patent/EP4216959A1/en active Pending
- 2021-09-24 US US18/246,190 patent/US20240009204A1/en active Pending
- 2021-09-24 WO PCT/US2021/051868 patent/WO2022066987A1/en active Application Filing
- 2021-09-24 KR KR1020237013405A patent/KR20230074518A/ko unknown
- 2021-09-24 MX MX2023003350A patent/MX2023003350A/es unknown
- 2021-09-24 JP JP2023518331A patent/JP2023542937A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4216959A1 (en) | 2023-08-02 |
KR20230074518A (ko) | 2023-05-30 |
CA3193237A1 (en) | 2022-03-31 |
US20240009204A1 (en) | 2024-01-11 |
CN116209428A (zh) | 2023-06-02 |
AU2021349936A1 (en) | 2023-03-30 |
WO2022066987A1 (en) | 2022-03-31 |
JP2023542937A (ja) | 2023-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005624A (es) | Tratamiento de vomito y nausea con una dosis minima de olanzapina. | |
MX2022001607A (es) | Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola. | |
AU2018238202A8 (en) | Combination therapy for the treatment or prevention of tumours | |
BR112021020247A2 (pt) | Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos | |
EP4223297A3 (en) | Administration and dosage of diaminophenothiazines | |
MX2018012719A (es) | Ram negativas para tratar la dermatitis atopica. | |
MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
MX2020011016A (es) | Composiciones para el tratamiento de condiciones de la piel. | |
MX2021016049A (es) | Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas. | |
MX2022001004A (es) | Inhibidores de enzimas. | |
MX2020001727A (es) | Terapia de combinacion. | |
MX2023007162A (es) | Macrociclos y sus usos. | |
AU2018271862A1 (en) | Combination therapy | |
MX2022006176A (es) | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. | |
MX2021009626A (es) | Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas. | |
MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
EA202190171A1 (ru) | Применение грамотрицательных видов для лечения атопического дерматита | |
MX2022006853A (es) | Macrociclos para uso en el tratamiento de enfermedades. | |
WO2023122260A3 (en) | Inhibitors of sars-cov-2 | |
MX2023000503A (es) | Macrociclos y su uso. | |
MX2023003350A (es) | Tratamiento para el vomito y la nausea con una dosis minima de olanzapina. | |
WO2018062876A3 (ko) | 통증이 경감되는 골관절염 치료용 키트 | |
MX2022005250A (es) | Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. | |
PH12021551093A1 (en) | Modulators of foxp3 expression |